­
­
­
­

Inventi Impact - Infectious Diseases & Immunology
(Formerly Inventi Rapid/Impact: Infection)

Patent Watch

  • NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION

    Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that specifically target human cyclophilin A (CyPA) to effectively inhibit Hepatitis C (HCV) infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or as pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with known delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided.

  • Method of Disinfection or Infection Control Against Norovirus

    An anti-norovirus agent that has high norovirus-inactivating activity and is safe for the human body, and an anti-norovirus composition that contains the anti-norovirus agent and is useful for disinfection and infection control against the norovirus. The anti-norovirus agent includes, as an active ingredient, an extract from a plant of the genus Diospyros containing tannin (hereinafter referred to as a "persimmon extract"), preferably a persimmon extract produced by heating squeezed juice or an extract from the fruit of a plant of the genus Diospyros or treating the squeezed juice or the extract with an alcohol. The anti-norovirus composition contains the anti-norovirus agent and at least one selected from the group consisting of alcohols, surfactants, antimicrobial agents, humectants, and cosmetic fats and oils, and preferably further containing an organic acid, such as citric acid, and/or a salt thereof or vitamin C.

  • COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION

    Compounds from 14 Kenyan plants, including from the root of Dovyalis abyssinica and Clutia robusta have been characterized and isolated, and their uses are disclosed.

  • RAPID TEST FOR DETECTING INFECTION

    Test kit has a cellulose filter paper with a flow rate of about 0.04 to about 0.4 ml/min/cm.sup.2, such that rapid screening may be made using bodily fluids, such as blood, serum and plasma. A process for using a rapid test kit may include a buffer diluting a sample and presenting it directly on a test area of the test kit, then adding a staining reagent, such as protein A conjugated with colloidal gold, and adding a destaining buffer. The rapid test uses whole blood, serum and plasma and is completed in less than two minutes. The use of whole blood provides for a test procedure capable of being used in the field and in doctor's offices as a simple, inexpensive screening test

  • VACCINE FOR CHIKUNGUNYA VIRUS INFECTION

    The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikun-gunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikun-gunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus.

  • METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29 CYSTEINE MUTANTS

    IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

  • CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST HUMAN CYTOMEGALOVIRUS INFECTION

    The invention relates to plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens, which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of any of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods of inducing an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators.

  • COMPOSITION AND METHODS OF INHIBITING GASTROINTESTINAL PATHOGEN INFECTION

    Compositions comprising a milk-derived oligosaccharide such as trifucosyl(1,2-1,2-1,3)-lacto-N-octoase (TFiLNO) and uses thereof for inhibiting invasion of gastrointestinal pathogen into intestinal epithelial cells or for treating an infectious disease (e.g., a disease caused by a gastrointestinal pathogen such as an ETEC) or an inflammatory diseases such as inflammatory bowel disease.

  • ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION

    The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the Filoviridae family, including Ebola and Marburg viruses. The compounds, compositions, and methods also relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds include phosphorodiamidate morpholino oligonucleotides (PMOplus) having a nuclease resistant backbone, about 15-40 nucleotide bases, at least two but typically no more than half piperazine-containing intersubunit linkages, and a targeting sequence that is targeted against the AUG start site region of Ebola virus VP35, Ebola virus VP24, Marburg virus VP24, or Marburg virus NP, including combinations and mixtures thereof.

  • THERAPIES FOR PREVENTING OR SUPPRESSING CLOSTRIDIUM DIFFICILE INFECTION

    The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of C. difficile infection wherein the antibodies bind to a C. difficile toxin, and wherein said prevention or treatment is by oral delivery of the antibody composition. Also provided is a pharmaceutical composition of ovine antibodies for oral delivery, which further comprises one or more means for protecting the antibodies from trypsin and/or chymotrypsin and/or stomach acid.

  • METHODS FOR PREVENTING AND TREATING STAPHYLOCOCCUS AUREUS COLONIZATION, INFECTION, AND DISEASE

    The invention provided herein relates to a method of preventing a Staphylococcus aureus colonization and/or infection by administering a Streptococcus pneumoniae strain, antigen thereof, or homologous staphylococcal antigen. The invention further relates to a method of treating a disease associated with a Staphylococcus aureus colonization and/or infection by administering a Streptococcus pneumoniae strain, antigen thereof, or homologous staphylococcal antigen.

  • TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE

    The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.

  • AGENT FOR TREATING HCV INFECTION

    Provided is an imidazolylbenzene compound or salt thereof that controls HCV replication and in addition is particularly capable of strongly controlling HCV replication, and is very effective in the prevention and treatment of HCV infection when used in combination with another agent for treating HCV infection such as Interferon.

  • NANO-ENCAPSULATED THERAPEUTICS FOR CONTROLLED TREATMENT OF INFECTION AND OTHER DISEASES

    This invention relates to a method to provide immediate, direct and controlled time release of an effective amount of therapeutics to a wound site for a prolonged period. The pharmaceutical formulation comprising a plurality of nanoparticles, said nanoparticles encapsulating a therapeutically effective amount of one or more antibacterial agents, and an application of the formulation to an implant before surgery provide for extended release of said antibacterial agents.

  • COMPOSITIONS AND METHODS FOR REDUCING AND DETECTING VIRAL INFECTION

    The invention provides methods and compositions for screening candidate compounds for activity in altering the level of expression of Schlafen (Slfn) in cells, tissues and animals. The invention also provides methods and compositions for screening candidate compounds for activity in altering the level of virus infection. The invention further provides methods and compositions for screening candidate compounds for altering the level of expression of virus proteins without substantially unfaltering the level of expression of cellular proteins. The invention additionally provides methods and compositions for diagnosing the risk and/or susceptibility to virus infection. The invention also provides transgenic non-human animals, and transgenic cells, comprising a mutant Schlafen (Slfn) gene, such as a knockout mutation. These invention's compositions and methods are useful as models for virus infection, and for screening candidate prophylactic and/or therapeutic anti-viral compounds.

  • SELECTIVELY SCANNING OBJECTS FOR INFECTION BY MALWARE

    Techniques are described herein that are capable of selectively scanning objects for infection by malware (i.e., to determine whether one or more of the objects are infected by malware). For instance, metadata that is associated with the objects may be reviewed to determine whether update(s) have been made with regard to the objects since a determination was made that the objects were not infected by malware. An update may involve increasing a number of the objects, modifying one of the objects, etc. Objects that have been updated (e.g., added and/or modified) since the determination may be scanned. Objects that have not been updated since the determination need not necessarily be scanned. For instance, an allowance may be made to perform operations with respect to the objects that have not been updated since the determination without first scanning the objects for infection by malware.

  • Methods and Reagents for Diagnosing Hantavirus Infection

    Novel methods and immunodiagnostic test kits for the detection of hantavirus infection are disclosed. The methods and kits employ combinations of recombinant N and/or G1 antigens from at least six different hantavirus serotypes, including Hantann (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV). Additional hantavirus antigens from these and other hantavirus types may also be present. The methods provide for highly accurate results and allow the detection of infection so that treatment can be administered and death avoided.

  • VACCINE AND METHODS TO REDUCE CAMPYLOBACTER INFECTION

    Vaccine vectors and methods for enhancing resistance to Campylobacter infection or for enhancing the immune response to Campylobacter are provided herein. The vaccine vectors include a first polynucleotide which encodes an antigenic polypeptide selected from SEQ ID NO 7-9 or a fragment thereof. The vector may also include an immunostimulatory polypeptide. The methods include administering the vaccine vectors to a subject.

  • VACCINE AND METHODS TO REDUCE CAMPYLOBACTER INFECTION

    Vaccine vectors and methods for enhancing resistance to Campylobacter infection or for enhancing the immune response to Campylobacter are provided herein. The vaccine vectors include a first polynucleotide which encodes an antigenic polypeptide selected from SEQ ID NO 7-9 or a fragment thereof. The vector may also include an immunostimulatory polypeptide. The methods include administering the vaccine vectors to a subject.

  • Infection Prevention System with IV Pole Flush and Swab Caddy

    A bed-side system for preventing infection that uses a flush and swab caddy attached to an IV pole or other bed-side equipment. By providing convenient and secure storage for pre-filled syringes, alcohol swabs, and other medical supplies, it can improve individual patient care. In an embodiment, the caddy attaches to the IV pole and comprises a locking compartment for pre-filled syringes and an open tray for alcohol swabs and other medical supplies. The syringes may be filled with saline, heparin, or another solution.

  • NUCLEIC ACID MOLECULES, POLYPEPTIDES, ANTIBODIES AND COMPOSITIONS FOR TREATING AND DETECTING INFLUENZA VIRUS INFECTION

    Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection.

  • METHOD FOR ASSAYING LOWER RESPIRATORY TRACT INFECTION OR INFLAMMATION

    The present invention relates to a reliable method of prediction of lower respiratory tract infection or inflammation in humans, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum, and a high level is indicative of the development and the severity of the disease, allowing the classification of patients according to risk.

  • SYSTEMS AND METHODS FOR TREATING PATHOGENIC INFECTION

    The present invention relates to a reliable method of prediction of lower respiratory tract infection or inflammation in humans, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum, and a high level is indicative of the development and the severity of the disease, allowing the classification of patients according to risk.

  • SYSTEMS AND METHODS FOR TREATING PATHOGENIC INFECTION

    An internal anatomic target that is infected by pathogenic microorganisms is treated using an applicator configured for delivering a therapeutic solution thereto and an UV light-emitting device transmits UV light thereon.

  • COMPOSITIONS AND METHODS USEFUL FOR HCV INFECTION

    The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.

  • Methods and Compositions for Treatment of Human Immunodeficiency Virus Infection with Conjugated Antibodies or Antibody Fragments

    The present invention concerns methods and compositions for treatment of HIV infection in a subject. The compositions may comprise a targeting molecule against an HIV antigen, such as an anti-HIV antibody or antibody fragment. The anti-HIV antibody or fragment may be conjugated to a variety of cytotoxic agents, such as doxorubicin. In a preferred embodiment, the antibody or fragment is P4/D10. Other embodiments may concern methods of imaging, detection or diagnosis of HIV infection in a subject using an anti-HIV antibody or fragment conjugated to a diagnostic agent. In alternative embodiments, a bispecific antibody with at least one binding site for an HIV antigen and at least one binding site for a carrier molecule may be administered, optionally followed by a clearing agent, followed by administration of a carrier molecule conjugated to a therapeutic agent.

  • PREPARATION, USE OF PREPARATION FOR TREATMENT, AND METHOD OF TREATMENT OF INTESTINAL INFECTION

    A preparation for use in the treatment of clostridium difficile or salmonella infection comprising a mixture of galacto-oligosaccharide and matter from cranberry, and uses thereof.

  • Treatment of Plants Against Oomycete Infection

    The invention refers to a new strain of Phoma useful for manufacturing a plant-care composition intended to treat plants against phytopathogenic oomycetes. This new strain was deposited on Feb. 25, 2010 under the CNCM number 1-4278.

  • INFECTION ACTIVATED WOUND CARING COMPOSITIONS AND DEVICES

    Provided are wound caring compositions and devices containing a pH-sensitive, preferably acid degradable, components contained in a water-permeable and hydronium ion permeable material. The pH-sensitive component encloses an antibiotic which is released to the wound upon infection by a microorganism at the wound site, and/or encloses a pH indicator. The antibiotic release is triggered by the microorganism's production of CO.sub.2 at the wound site which forms carbonic acid, lowers the pH at the pH sensitive components, and thus results in rupture of the liposome.

  • METHODS AND KITS FOR THE DETECTION OF AN INFECTION IN SUBJECTS WITH LOW SPECIFIC ANTIBODY LEVELS

    This invention relates to methods that enable the detection of antibodies against a latent infection, a chronic infection, a re-infection, and/or a breakthrough infection; enable the diagnosis of a latent infection, a chronic infection, a re-infection, and/or a breakthrough infection; and increase low anti-viral antibody levels, and a kit for the detection of virus-specific antibodies expressed at low levels.

  • METHODS FOR TREATING INFECTION

    The present invention provides new methods and kits for treating and preventing bacterial infection.

  • METHODS FOR PREVENTING OR TREATING VIRAL INFECTION

    The present invention provides methods to prevent or treat flavivirus infection, and assays for identifying agents which treat flavivirus infection. The present invention also provides compositions for preventing flavivirus infection and a kit for screening an agent that prevents or treats viral infection.

  • METHODS FOR PREVENTING OR TREATING VIRAL INFECTION

    The present invention provides methods to prevent or treat flavivirus infection, and assays for identifying agents which treat flavivirus infection. The present invention also provides compositions for preventing flavivirus infection and a kit for screening an agent that prevents or treats viral infection.

  • ANTIBODIES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED INFECTION AND DISEASE

    Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.

  • A NOVEL CHIMERIC PROTEIN FOR PREVENTION AND TREATMENT OF HIV INFECTION

    This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an induced-binding domain, functionally linked by a peptide linker. Such proteins, nucleic acid molecules encoding them, and their production and use in preventing or treating viral infections are provided. One prototypical bispecific fusion protein is sCD4-SCFv(17b), in which a soluble CD4 fragment (containing domains D1 and D2) is fused to a single chain Fv portion of antibody 17b via a linker.

  • CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION

    The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

  • COMPOSITIONS AND METHODS FOR INHIBITING VIRAL INFECTION

    Provided herein are compositions and methods for inhibiting viral infection of a host cell. The methods comprise contacting the the host cell with an effective amount of one or more polypeptides having a disintegrin domain. The polypeptide can be CN, VCN or modified ADAM-derived polypeptide (MAP), or a fusion protein comprising a CN, VCN or MAP.

  • METHOD OF TREATING HERPES VIRUS INFECTION USING MACROCYCLIC LACTONE COMPOUND

    A method of treating herpes simplex virus infection or varicella zoster virus infection is disclosed. The method includes topically applying a composition containing an effective amount of one or more macrocyclic lactone compounds, including avermectin compounds or milbemycin compounds and a pharmaceutically acceptable carrier to the affected area of an individual suffering from herpes simplex virus infection or varicella zoster virus infection.

  • METHODS AND COMPOSITIONS FOR REGULATING HIV INFECTION

    Methods and compositions for regulating HIV infection and/or replication in which an anti-HIV transgene is integrated into the genome of a cell using a nuclease.

  • COMPOSITIONS AND METHODS FOR DETECTING VIRAL INFECTION USING DIRECT-LABEL FLUORESCENCE IN SITU HYBRIDIZATION

    The present invention relates generally to assays for the detection of viral infection and/or prognosis of viral infection and associated disease states. In particular, the invention relates to directly labeled viral-related nucleic acids having significant diagnostic, prognostic, and screening utilities and methods of using the same.

  • Antiviral Drugs for Treatment of Arenavirus Infection

    Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, and Pichinde), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).

  • SYSTEM AND METHOD TO ENABLE DETECTION OF VIRAL INFECTION BY USERS OF ELECTRONIC COMMUNICATION DEVICES

    A non-transitory computer readable medium that stores instructions for causing a computerized system to perform the following operations: determining, by the computerized system, that a first person is infected by a first infectious disease; wherein the determination is associated with a first person infection probability attribute; detecting, by the computerized system, based upon location information collected during at least a portion of a first infectious disease manifestation period, the location information being indicative of locations of the first person and other persons, a second person that was within an infection distance from the first person and is potentially infected by the first infectious disease; calculating, by the computerized system, a second person infection probability attribute; and updating, by the computerized system, the first person infection probability attribute in response to the second person infection probability attribute.

  • ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR TREATMENT OF PATHOGENIC INFECTION

    The invention provides compositions and methods for the prophylaxis or treatment of diseases or disorders in a subject (e.g., a mammal, such as a human) including, e.g., diseases or disorders caused by biological agents, autoimmune diseases, and cancer. The compositions include a delivery vector (e.g., a viral vector, such as an Ad5 vector) encoding an interferon (e.g., IFN-.alpha.), and are provided to the subject by, e.g., intranasal or pulmonary administration.

  • 3',5'-CYCLIC PHOSPHORAMIDATE PRODRUGS FOR HCV INFECTION

    Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

  • Yeast-Based Therapeutic for Chronic Hepatitis C Infection

    Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.

  • USING A CYTOKINE SIGNATURE TO DIAGNOSE DISEASE OR INFECTION

    Provided are methods and compositions for detection of levels, activity, or expression of cytokines so as to determine a cytokine signature. A cytokine signature of a subject can be compared to a control or reference value(s) and differences there between used in the diagnosis or monitoring of a neuroimmune disease or a retroviral infection.

  • Antiviral Drugs for Treatement or Prevention of Dengue Infection

    Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.

  • Method for Disinfection or Infection Control Against a Non-Enveloped Virus"

    Provided herein is a method for disinfection or infection control against a non-enveloped virus using a composition including, as an active ingredient, a persimmon extract containing tannin from an astringent fruit of a plant of the genus Diospyros, such as the plant Diospyros kaki. The non-enveloped virus is a non-enveloped virus belonging to the genus Betanodavirus, Aquavirnavirus, Ranavirus, Enterovirus, Mastadenovirus, Vesivirus, or Rotavirus. In certain embodiments, the persimmon extract is prepared by heating a squeezed juice or an extract from an astringent fruit of a plant of the genus Diospyros, or obtained by treating a squeezed juice or an extract from an astringent fruit of the plant of the genus Diospyros with an alcohol, in order to inactivate an enzyme contained therein. The persimmon extract may also contain at least condensed tannin.

  • ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS

    The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient that has genetic variations located near the IL28B gene, including SNP rs12979860 with a CC or non-CC genotype and SNP rs8099917 with a TT or non-TT genotype.

  • METHODS OF TREATING AND PREVENTING RHINOVIRUS INFECTION

    The present invention relates to methods of treating or preventing non-enveloped viral infection and/or disease caused by non-enveloped virus infection, particularly a viral infection caused by rhino virus. The methods comprise administering to an individual in need thereof an effective amount of a defensin peptide. The defensin peptide may be selected from .alpha.-, .beta.-, or .theta.-defensins.

  • MAMMALIAN GENES INVOLVED IN INFECTION

    The present invention relates to cellular proteins that are involved in infection or are otherwise associated with the life cycle of one or more pathogens.

  • METHODS FOR TREATING BACTERIAL INFECTION

    This invention relates to methods for treating bacterial infection, which methods find utility in the treatment of, for example, infected ulcers, optionally infected diabetic ulcers. In particular, this invention relates to treating bacterial infection, for example, infected diabetic ulcers by topical administration of at least one aminoglycoside antibiotic at the site of infection, in combination with at least one antibacterial agent, which antibacterial agent is administered remote from the site of infection, preferably administered systemically. In a particular embodiment, the present invention relates to a composition for use in treating bacterial infection, the composition comprising gentamicin sulphate (a water-soluble broad-spectrum aminoglycoside antibiotic) uniformly dispersed in a type-I collagen matrix; incombination with at least one systemically-administered antibacterial agent. The present invention provides bactericidal activity against most strains of aerobic gram-negative and gram-positive and facultative anaerobic gram-negative pathogens, including methicillin-resistant Staphylococcus aureus.

  • METHODS OF DIAGNOSING CLOSTRIDIUM DIFFICILE INFECTION

    Methods of diagnosing Clostridium difficile infection and compounds used in the methods are provided. The diagnostic methods are specific and sensitive methods for detecting a host cell response and, in some aspects, a target response, i.e. a Clostridium difficile toxin, in an individual infected with Clostridium difficile. The methods comprise detecting in a stool specimen or fluid exposed to the stool specimen a Clostridium difficile toxin, or a fragment thereof, and an increase in a colonic epithelial cell protein exemplified by a non-muscle tropomyosin. Also provided are kits comprising reagents for detecting host cell proteins and Clostridium difficile toxins.

  • COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION

    This invention relates to a compound of Formula 1A: ##STR00001## or a pharmaceutically acceptable salt thereof; wherein R1 to R4, R7, R9 to R12 and Y are as defined herein. The invention further relates to pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof; and method of using same for reducing or reversing bacterial resistance to at least one aminoglycoside antibiotic.

  • TREATMENT FOR INFECTION WITH HEPATITIS B VIRUS ALONE OR IN COMBINATION WITH HEPATITIS DELTA VIRUS AND ASSOCIATED LIVER DISEASES

    The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis B and Hepatitis D virus infections.

  • CHIMERIC PROMOTERS CAPABLE OF MEDIATING GENE EXPRESSION IN PLANTS UPON PATHOGEN INFECTION AND USES THEREOF

    Described are synthetic promoters capable of mediating gene expression in plants upon pathogen infection. Furthermore, recombinant genes and vectors comprising said chimeric promoters as well as host cells transformed with such chimeric promoters, recombinant genes, or vectors are provided. Additionally, diagnostic compositions and kits comprising such chimeric promoters, recombinant genes, vectors or cells are described. Provided are further methods for the identification of compounds being capable of activating or inhibiting genes that are specifically expressed in plants upon pathogen infection employing the above described means. Furthermore, transgenic plant cells, plant tissue, and plants containing the above-described chimeric promoters, recombinant genes, and vectors as well as the use of the aforementioned chimeric promoters, recombinant genes, vectors and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding, and/or agriculture are described.

  • SERPIN DRUGS FOR TREATMENT OF VIRAL INFECTION AND METHOD OF USE THEREOF

    The invention includes a heparin activated Antithrombin III encapsulated into a sterically stabilized anti-HLA-DR immunoliposome for the treatment of a HIV infection in a human patient

  • ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION

    The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the Filoviridae family, including Ebola and Marburg viruses. The compounds, compositions, and methods also relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds include phosphorodiamidate morpholino oligonucleotides (PMOplus) having a nuclease resistant backbone, about 15-40 nucleotide bases, at least two but typically no more than half piperazine-containing intersubunit linkages, and a targeting sequence that is targeted against the AUG start site region of Ebola virus VP35, Ebola virus VP24, Marburg virus VP24, or Marburg virus NP, including combinations and mixtures thereof.